Patent EP0213921A2 successfully refreshed from Google Patents.
EP0213921A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Modulation of virus-related events by double-stranded RNAs
Assignee: Hem Research Inc
•
Filing: 1986-08-26
•
Granted: —
•
Expires: 2006-08-26
Abstract
Abstract The use of mismatched dsRNA, e.g. Ampligen for the manufacture of compositions for use in the Selective activation of a latent natural defense system within human cells, both cells already infected with AIDS virus as well as cells at risk to infection. Specific treatments for various clinical phases of the biological continuum of AIDS virus-related events ranging from subtle, early immunological lesions to advanced disease are described. Prophylaxis or prevention of AIDS virus related events, such as by introduction of mis- matched double-stranded RNA into various blood products or biological fluids to be used in man (e.g., blood transfusion) or around man (e.g., dialysis programs) are also described.
Inventors
- 👤 William A. Carter
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 01:19
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/21; A61L; A61L2/00; A61L2/16; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18; A61P37/00; A61L2103/00; A61L2103/05; A61L2103/09
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
30 words
The use of a dsRNA in the manufacture of a composition for use in the treatment of retrovirus or T-cell lymphotropic virus induced conditions, e.g. AIDS, by therapy or prophylaxis.
Claim 2
Dependent Claim
30 words
The use of a dsRNA in the manufacture of a composition for use in the treatment of retrovirus or T-cell lymphotropic virus induced conditions, e.g. AIDS, by therapy or prophylaxis.
Claim 3
Dependent Claim
16 words
Use of a dsRNA as claimed in Claim 1 wherein the dsRNA is a mismatched dsRNA.
Claim 4
Dependent Claim
40 words
Use of a dsRNA as claimed in Claim 2 wherein the dsRNA is a complex of a polyinosinate and a polycytidylate containing a proportion of uracil or guandidine bases e.g. from 1 in 5 to 1 in 30 such bases.
Claim 5
Dependent Claim
24 words
Use of a dsRNA as claimed in Claim 3, wherein the dsRNA is of the general formula rI n .(C 12 U) n .
Claim 6
Dependent Claim
22 words
Use of a dsRNA as claimed in any preceding claim, wherein the composition comprises the dsRNA and an AIDS inhibition assisting agent.
Claim 7
Dependent Claim
16 words
Use of a dsRNA as claimed in Claim 5, wherein said assisting agent is a lymphokine.
Claim 8
Dependent Claim
18 words
Use of a dsRNA as claimed in Claim 6, wherein the lymphokine is an interferon or an interleukin.
Claim 9
Dependent Claim
35 words
The use of dsRNA as claimed in Claim 7, wherein the composition contains the dsRNA and an interferon in the ratio of 0.01 to 1000 micrograms of dsRNA to 0.1 to 100,000 IRU of interferon.
Claim 10
Independent Claim
58 words
A method of rendering a biological fluid or cells resistant to infection with retrovirus or T-cell lymphotropic virus, e.g. AIDS virus, enhancing the resistance thereof, or mitigating the effect of infection therefrom comprising admixing or contacting said biological fluid or cells with an effective amount of a dsRNA as defined in any one of Claims 1 to 4.
Claim 11
Dependent Claim
35 words
A method as claimed in Claim 9 in which the biological fluid is human blood or a fraction thereof, or the cells are NK cells, T-cells, T-suppressor cells, T-helper cells, spermatozoa, ova or fetal cells.
Claim 12
Dependent Claim
22 words
As a composition of matter, human blood or a fraction thereof or human cells and an effective amount of a mismatched dsRNA.
Claim 13
Dependent Claim
22 words
As a composition of matter, human blood or a fraction thereof or human cells and an effective amount of a mismatched dsRNA.
Claim 14
Dependent Claim
42 words
A process of removing or inactivating retroviruses or T-cell lymphotropic viruses, e.g. AIDS viruses from a device for handling parenteral fluids or mitigating the effect of infection therefrom comprising contacting said device with a composition containing an effective amount of a dsRNA.
Claim 15
Dependent Claim
42 words
A process of removing or inactivating retroviruses or T-cell lymphotropic viruses, e.g. AIDS viruses from a device for handling parenteral fluids or mitigating the effect of infection therefrom comprising contacting said device with a composition containing an effective amount of a dsRNA.
Claim 16
Dependent Claim
27 words
The use of dsRNA in the manufacture of a medicament for restoring an anergic immune state to a substantially normal immune state, as measured by skin testing.
Claim 17
Dependent Claim
27 words
The use of dsRNA in the manufacture of a medicament for restoring an anergic immune state to a substantially normal immune state, as measured by skin testing.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.